Q2 FY2026 EarningsQ2 FY26 performance beat consensus estimates on both top and bottom lines: revenue was $76.4M vs. $72.7M expected, and diluted EPS loss of $0.28 was significantly narrower than the $0.65 consensus loss. Despite a 27.6% YoY revenue decline due to a 48.7% drop in active earning coaches, productivity per coach rose 41% YoY. Management's Q3 revenue guidance of $60M-$80M encompasses the $72.7M consensus, while the outlook for a return to profitability in Q4 FY26 indicates a potential inflection point in the business turnaround.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Medifast(MED) the Revenue is 76.38 M (-27.64%), Beat estimate;the EBIT is -4.327 M (-305.9%), Beat estimate;the EPS is -0.28 (-227.3%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.08B27.64%
0.07B31.13%
+0.00B3.49%
EBITExceed expectations
-0.00B305.91%
-0.01B622.33%
+0.00B316.42%
EPSExceed expectations
-0.28227.27%
-0.65395.45%
+0.3700168.18%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf